

Résultats: Cinquante pourcent des membres du Hope Club (bras 1 : 48,3%, bras 2 : 52,2%) ont été dépistés positifs pour la dépression au début de l'étude, contre 36,5% des non-membres du Hope Club. Aucune différence statistiquement significative n'a été constatée dans les mesu961Tm[(Aucu.a90m2.425J/GS4gs/CS1cs1scn/F31Tf6.3761006.376119



Figure 3. Distribution of Zanme Lasante Depression Symptom Inventory (ZLDSI) scores, by study arm and survey time point. Mean scores represented as hollow white circles.

Among Hope Club members at baseline, no statistically significant demographic characteristics or measurement scores were detected across study arms (Table 2). Both Arms were predominantly composed of female participants (95.8% and 91.3% in Arms 1 and 2, respectively), who ranged in age from 24 to 97 y. More than 74% of Hope Club members in each arm reported SRH as Fair (Arm 1: 53.4%, Arm 2: 55.4%) or Poor (Arm 1: 21.2%, Arm 2: 26.1%). A positive trend from Poor to Fair was observed at midpoint and endpoint in both arms, with SRH reported as Poor reduced to 12.8% and 19.0% in each Arm at 8.96649961208.1198307.287Tm[()TJ/GS8gs0g0.0001Tc/Fb2162.8683274.41Tm[()TJ/GS8gs0g

acrTm.966((study)]TJ/GS5gs/CS1cs1scn0Tc/F31Tf

8.96649961208.1198307.287Tm[()TJ/GS8gs0g0.0001Tc/Fb2162.8683274.41Tm[()TJ/GS8gs0g

Table 3. Effect of the chronic disease self-management program (CDSMP) on the study measures, among Hope Club members living with LF in Léogâne, Haiti

Measure	Adjusted risk or OR ^a (95% CI)	p-value
SRH	1.02 (0.48–2.1)	NS
Excellent		
Very Good		
Good		
Fair		
Poor		
ZLDSI	0.52 (0.07–3.7)	NS
Depressive illness (ZLDSI \geq 13)	1.0 (0.39–2.6)	NS
SMCDS	0.71 (0.89–2.3)	NS
MSPSS		
Family	0.74 (0.21–2.6)	NS
Friends	1.8 (0.32–10.2)	NS
Significant person	0.42 (0.12–1.5)	NS
DLQI	0.96 (0.45–2.0)	NS
No effect		
Small effect		
Moderate effect		
Very large effect		
Extremely large effect		
DLQI	0.78 (0.20–3.0)	NS

Abbreviations: DLQI, Dermatology

lower limb disorder caused by lymphatic filariasis, podoconiosis, and leprosy in Ethiopia: Results from the EnDPoINT pilot cohort study.